BR9909342A - Vacinas adn adjuvadas - Google Patents

Vacinas adn adjuvadas

Info

Publication number
BR9909342A
BR9909342A BR9909342-1A BR9909342A BR9909342A BR 9909342 A BR9909342 A BR 9909342A BR 9909342 A BR9909342 A BR 9909342A BR 9909342 A BR9909342 A BR 9909342A
Authority
BR
Brazil
Prior art keywords
dna vaccines
dna
auxiliary compound
adjuvant
adjuvant dna
Prior art date
Application number
BR9909342-1A
Other languages
English (en)
Inventor
Jean-Christophe Franc Audonnet
Jules Maarten Minke
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9525029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9909342(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Sas filed Critical Merial Sas
Publication of BR9909342A publication Critical patent/BR9909342A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"VACINAS ADN ADJUVADAS"<D>. A vacina ADN compreende um ADN desprotegido, incorporando e expressando in vivo uma seq³ência nucleotídica, codificando para um polipeptídeo antigênico, de preferência um gene de um agente patogênico, e pelo menos um composto auxiliar escolhido dentre os polímeros acrílico ou metacrílico e os copolímeros de anidrido maléico e de derivado alcenila. O composto auxiliar é, de preferência, um carbómero ou um EMA(r).
BR9909342-1A 1998-04-03 1999-03-22 Vacinas adn adjuvadas BR9909342A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9804409A FR2776928B1 (fr) 1998-04-03 1998-04-03 Vaccins adn adjuves
PCT/FR1999/000666 WO1999051269A1 (fr) 1998-04-03 1999-03-22 Vaccins adn adjuves

Publications (1)

Publication Number Publication Date
BR9909342A true BR9909342A (pt) 2000-12-12

Family

ID=9525029

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909342-1A BR9909342A (pt) 1998-04-03 1999-03-22 Vacinas adn adjuvadas

Country Status (17)

Country Link
US (1) US7163926B1 (pt)
EP (1) EP1066055B1 (pt)
JP (1) JP2002510651A (pt)
AR (1) AR037062A1 (pt)
AT (1) ATE353670T1 (pt)
AU (1) AU744964B2 (pt)
BR (1) BR9909342A (pt)
CA (1) CA2327389C (pt)
CY (1) CY1108013T1 (pt)
DE (1) DE69935136T2 (pt)
DK (1) DK1066055T3 (pt)
ES (1) ES2283105T3 (pt)
FR (1) FR2776928B1 (pt)
PL (1) PL194348B1 (pt)
PT (1) PT1066055E (pt)
WO (1) WO1999051269A1 (pt)
ZA (1) ZA992478B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804026B1 (fr) * 2000-01-21 2004-06-11 Merial Sas Vaccination contre l'herpesvirose canine et vaccins
US6551598B2 (en) 2000-01-21 2003-04-22 Merial Vaccination against canine herpesvirosis and vaccines therefor
CN1638780A (zh) * 2001-12-14 2005-07-13 遗传电子公司 用脉冲电场进行颗粒辅助的多核苷酸免疫的方法
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
UA100370C2 (uk) 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
GB0805356D0 (en) * 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
US8603808B2 (en) 2008-05-08 2013-12-10 Merial Limited Leishmania vaccine using sand fly salivary immunogen
AP3334A (en) * 2008-10-24 2015-07-31 Univ California Vaccine against african horse sickness virus
BR112014001287B1 (pt) 2011-07-20 2020-12-08 Centre National De La Recherche Scientifique vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
US20130177591A1 (en) 2012-01-10 2013-07-11 Merial Limited Lipid Based Adjuvants for DNA Plasmids
ES2711878T3 (es) 2012-03-20 2019-05-08 Merial Inc Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma
KR102208844B1 (ko) 2012-08-30 2021-01-27 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 고압 디바이스 및 불활성화된 백신을 생산하고 재조합 단백질을 리폴딩/가용화하는 방법
WO2016210097A1 (en) * 2015-06-23 2016-12-29 The Trustees Of Columbia University In The City Of New York Novel equine parvovirus and uses thereof
LT3471760T (lt) 2016-06-17 2025-02-25 Boehringer Ingelheim Vetmedica Gmbh Nauji imunogeniniai preparatai, apimantys linijinių arba šakotų poliakrilo rūgšties polimerų adjuvantus
JP2023532878A (ja) * 2020-07-07 2023-08-01 アミリス，インコーポレイティド ワクチンアジュバントならびにそれを合成及び使用する方法
CN114272368A (zh) * 2021-12-16 2022-04-05 成都博宠生物科技有限公司 一种猪瘟和猪伪狂犬二联疫苗及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
ZA881694B (en) * 1987-03-17 1988-09-06 Akzo N.V. Adjuvant mixture
US6004563A (en) * 1990-11-07 1999-12-21 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
EP0532833A1 (en) * 1991-05-28 1993-03-24 Miles Inc. Vaccine for equine rhinopneumonitis
ATE259417T1 (de) * 1992-06-01 2004-02-15 Univ Melbourne Immunologisches verfahren für die detektion von pferde-herpesvirus typ 1 und 4 glycoprotein g antikörper
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
BE1008977A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US6300118B1 (en) * 1995-06-07 2001-10-09 American Home Products Corporation Plasmids comprising a genetically altered feline immunodeficiency virus genome
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998056931A1 (en) * 1997-06-11 1998-12-17 Institut Pasteur Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
AU8392898A (en) * 1997-07-14 1999-02-10 Powerject Vaccines, Inc. Method of dna vaccination using dna encoding antigen and encoding il6
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
US6444799B1 (en) * 1997-12-31 2002-09-03 Csl Limited P. gingivalis polynucleotides and uses thereof

Also Published As

Publication number Publication date
DE69935136T2 (de) 2007-11-29
EP1066055B1 (fr) 2007-02-14
CA2327389A1 (en) 1999-10-14
ES2283105T3 (es) 2007-10-16
AU744964B2 (en) 2002-03-07
PT1066055E (pt) 2007-05-31
WO1999051269A1 (fr) 1999-10-14
PL343602A1 (en) 2001-08-27
ZA992478B (en) 2000-10-10
FR2776928A1 (fr) 1999-10-08
DK1066055T3 (da) 2007-06-11
ATE353670T1 (de) 2007-03-15
FR2776928B1 (fr) 2000-06-23
CY1108013T1 (el) 2013-09-04
AU2844899A (en) 1999-10-25
JP2002510651A (ja) 2002-04-09
DE69935136D1 (de) 2007-03-29
CA2327389C (en) 2011-06-14
AR037062A1 (es) 2004-10-20
EP1066055A1 (fr) 2001-01-10
US7163926B1 (en) 2007-01-16
PL194348B1 (pl) 2007-05-31

Similar Documents

Publication Publication Date Title
CY1108013T1 (el) Dna εμβολια για τους ιππους που περιεχουν ανοσοενισχυτικους παραγοντες με πολυμερη του ακρυλικου ή μεθακρυλικου οξεος ή του εμα(r)
BR9611845A (pt) Vacina viva recombinante à base de herpesvírus felino de tipo 1 notadamente contra a peritonite infecciosa felina
ATE141946T1 (de) Hiv-2-virusvarianten
BR9908496A (pt) Vacinas vivas recombinadas e adjuvadas
EE05411B1 (et) Retseptori nukleiinhapped ja polpeptiidid
HUP0300120A3 (en) Altered strain of the modified vaccina virus ankara (mva)
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
SI1108035T1 (sl) Zdravljenje raka materničnega vratu
NZ502259A (en) Selectively hardened nail with one axial portion having hardness of at least 40 Rockwell C, and another axial portion having hardness of 35 Rockwell C maximum
AU6867801A (en) Fusion proteins of mycobacterium tuberculosis
DE69931639D1 (en) Ehrlichia canis protein
NO944245L (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
AR003135A1 (es) Baculovirus recombinante, una vacuna que los contiene, y el uso del mismo para preparar una vacuna util para evitar o disminuir la enfermedad causada porvirus de inmunodeficiencia felina.
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
ATE321844T1 (de) Rekombinanter schweinepockenvirus
TWI316089B (en) Capsid protein of feline calicivirus strain 431 and g1, dna fragments encoding them and immunogenic preparation comprising the same
EP0597016A4 (en) Infectious bursal disease virus recombinant poxvirus vaccine.
WO2003031569A3 (en) Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
WO2002035981A3 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
DK1248650T3 (da) Forbedrede DNA-vacciner til bovint herpesvirus 1
AU3261295A (en) Infectious peritonitis vaccine
EP1021526A4 (en) RECOMBINANT, GENETICALLY DELETED, PROVIRAL FeLV-DNA FOR THE PRODUCTION OF VACCINALS AGAINST FeLV.
FR2709132B1 (fr) Fragment d&#39;ADN portant le gène codant pour l&#39;enzyme de fragmentation du N-acétylhéparosane et les séquences adjacentes permettant son expression, enzyme recombinée et son utilisation.
ATE374622T1 (de) Genetische impstoffe mit adjuvans
IT1286307B1 (it) Virus mixomatoso ricombinante, suo impiego per la produzione di un vaccino e relativo vaccino.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]